4basebio PLC (AIM:4BB)

London flag London · Delayed Price · Currency is GBP · Price in GBX
985.00
-85.00 (-7.94%)
Jun 13, 2025, 5:08 PM GMT+1
-40.30%
Market Cap 152.45M
Revenue (ttm) 933.00K
Net Income (ttm) -12.33M
Shares Out 15.48M
EPS (ttm) -0.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,675
Average Volume 795
Open 1,075.00
Previous Close 1,070.00
Day's Range 985.00 - 1,080.00
52-Week Range 985.00 - 1,820.00
Beta 1.03
RSI 3.39
Earnings Date Jun 11, 2025

About 4basebio

4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally. The company offers hpDNA, double stranded linear DNA, covalently closed with single strand hairpins at the 5’ and 3’ ends for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA product for in vitro transcription processes for the production of mRNA for use in vaccine... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 110
Stock Exchange London Stock Exchange AIM
Ticker Symbol 4BB
Full Company Profile

Financial Performance

In 2024, 4basebio's revenue was 933,000, an increase of 84.39% compared to the previous year's 506,000. Losses were -12.33 million, 60.9% more than in 2023.

Financial Statements

News

There is no news available yet.